Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in [beta]-Thalassemia Major Patients: A Clinical Trial Crossover Study

Aim: Thalassemia is one of the most common genetic diseases, and cardiovascular disease (CVD) has been considered as the leading cause of mortality in more than 50% of [beta]-thalassemia patients. The aim of this study was to determine the effects of alpha-lipoic acid (ALA) on CVD risk factors in [b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of blood medicine 2020-05, p.131
Main Authors: Jamshidi, Khadijeh, Abdollahzad, Hadi, Nachvak, Mostafa, Rezaei, Mansour, Golpayegani, Mohammad Reza, Zahabi, Elham Sharifi
Format: Article
Language:English
Subjects:
Cardiovascular diseases
Clinical trials
Health aspects
Homocysteine
Iran
Medical research
Mortality
Risk factors
Thalassemia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: Thalassemia is one of the most common genetic diseases, and cardiovascular disease (CVD) has been considered as the leading cause of mortality in more than 50% of [beta]-thalassemia patients. The aim of this study was to determine the effects of alpha-lipoic acid (ALA) on CVD risk factors in [beta]-thalassemia major patients. Methods: Twenty [beta]-thalassemia major patients participated in this randomized crossover clinical trial study. Participants were randomly assigned to ALA (600 mg/day) or placebo groups for two 8-wk interventions that were separated by a 3-wk washout period. The CVD risk factors including serum osteoprotegerin (OPG), homocysteine, lipoprotein-associated phospholipase A2 and trimethylamine N-oxide were measured at the beginning and the end of each intervention phase according to the standard protocol. Results: Serum OPG reduced significantly in the ALA group in all participants (5.38 [+ or -] 2.79 to 3.27 [+ or -] 2.43 ng/mL, P= .003) and in the male subgroup (5.24 [+ or -] 2.56 to 3.13 [+ or -] 2.5 ng/mL, P= .015); this reduction was significant in comparison with the placebo group (P= .013). The changes in other CVD risk factors were not significant. Conclusion: The results of this study showed that after 8-wk of ALA consumption, the serum OPG reduced significantly in [beta]-thalassemia major patients. Therefore, controlling the serum OPG level with ALA consumption can be an important complementary therapeutic option to prevent the progression of CVD in [beta]-thalassemia major patients. Keywords: [beta]-thalassemia major, alpha-lipoic acid, CVD risk factors
ISSN:1179-2736
1179-2736
DOI:10.2147/JBM.S252105